The FDA has approved a once-monthly dose of Actonel (risedronate sodium tablets, from Procter & Gamble and sanofi-aventis) for the treatment and prevention of postmenopausal osteoporosis. The 150mg strength tablet taken monthly was shown to have similar increases in bone mineral density (BMD) as in patients taking a daily dosage regimen.

Other dosing regimens of Actonel are indicated to increase bone mass in men with osteoporosis, for the treatment and prevention of glucocorticoid-induced and postmenopausal osteoporosis, and for the treatment of Paget’s disease.

For more information call (877) ACTONEL or visit www.actonel.com.